LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company developing innovative therapies for inflammatory, fibrotic and ...
LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell ...
GR-0621 targets natural killer T cells, reducing inflammation and fibrosis in idiopathic pulmonary fibrosis (IPF). The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating ...
GRI Bio (GRI) announced the presentation of preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis. The data were ...
GRI Bio reports positive interim results for GRI-0621 in IPF treatment; patient enrollment nearing completion, cash runway extended to Q3 2025. Cash runway, although extended by a recent public ...
GRI Bio (GRI) announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis. The study met its primary endpoint and ...
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety ...
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results